1. Home
  2. ITRI vs CRSP Comparison

ITRI vs CRSP Comparison

Compare ITRI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Itron Inc.

ITRI

Itron Inc.

HOLD

Current Price

$97.77

Market Cap

4.4B

Sector

Industrials

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$55.54

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRI
CRSP
Founded
1977
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.1B
IPO Year
1993
2016

Fundamental Metrics

Financial Performance
Metric
ITRI
CRSP
Price
$97.77
$55.54
Analyst Decision
Buy
Buy
Analyst Count
10
19
Target Price
$135.78
$71.50
AVG Volume (30 Days)
476.3K
1.8M
Earning Date
02-17-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
14.43
N/A
EPS
5.57
N/A
Revenue
$2,408,401,000.00
$38,337,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.70
$1,376.73
P/E Ratio
$17.53
N/A
Revenue Growth
0.14
N/A
52 Week Low
$90.11
$30.04
52 Week High
$142.00
$78.48

Technical Indicators

Market Signals
Indicator
ITRI
CRSP
Relative Strength Index (RSI) 49.61 49.99
Support Level $96.31 $51.00
Resistance Level $101.21 $60.90
Average True Range (ATR) 2.58 3.28
MACD 0.34 0.23
Stochastic Oscillator 48.91 46.97

Price Performance

Historical Comparison
ITRI
CRSP

About ITRI Itron Inc.

Itron Inc provides solutions that measure, manage, and analyze energy and water use. It operates under the Itron brand and manages and reports under three operating segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment includes hardware products used for measurement, control, or sense that do not have communications capability embedded for use with broader Itron systems. The Networked Solutions segment includes a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution. The Outcome segment includes their value-added, enhanced software and services which manage, organize, analyze, and interpret data to improve decision-making and maximize operational profitability.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: